D
Y-mAbs Therapeutics, Inc.
YMAB
$4.73
-$0.18-3.67%
D
Sell
1/14/2025Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 1/14/2025 due to an increase in the valuation index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 1/14/2025 due to an increase in the valuation index.
E
Sell
12/13/2024Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 12/13/2024 due to a decline in the volatility index and total return index.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 12/13/2024 due to a decline in the volatility index and total return index.
D
Sell
11/26/2024Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 11/26/2024 due to a large increase in the total return index, solvency index and volatility index. The quick ratio increased from 2.3 to 3.48.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 11/26/2024 due to a large increase in the total return index, solvency index and volatility index. The quick ratio increased from 2.3 to 3.48.
E
Sell
1/9/2024Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 1/9/2024 due to a decline in the valuation index.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 1/9/2024 due to a decline in the valuation index.
D
Sell
6/23/2023Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 6/23/2023 due to an increase in the total return index, growth index and volatility index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 6/23/2023 due to an increase in the total return index, growth index and volatility index.
E
Sell
3/14/2023Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/23/2023Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
11/23/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 11/23/2022 due to a decline in the total return index and volatility index.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 11/23/2022 due to a decline in the total return index and volatility index.
D
Sell
11/3/2022Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 11/3/2022 due to an increase in the valuation index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 11/3/2022 due to an increase in the valuation index.
D
Sell
9/19/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 9/19/2022 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.6422 to -$0.9408, EBIT declined 44.23% from -$27.7M to -$39.95M, and the quick ratio declined from 5.72 to 4.78.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 9/19/2022 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.6422 to -$0.9408, EBIT declined 44.23% from -$27.7M to -$39.95M, and the quick ratio declined from 5.72 to 4.78.
D
Sell
6/21/2022Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 6/21/2022 due to an increase in the volatility index and total return index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 6/21/2022 due to an increase in the volatility index and total return index.
D
Sell
6/3/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 6/3/2022 due to a decline in the volatility index and valuation index.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 6/3/2022 due to a decline in the volatility index and valuation index.
D
Sell
5/16/2022Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 5/13/2022 due to a noticeable decline in the solvency index. The quick ratio declined from 6.79 to 5.72.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 5/13/2022 due to a noticeable decline in the solvency index. The quick ratio declined from 6.79 to 5.72.
D
Sell
5/5/2022Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 8.79 to 6.79.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 8.79 to 6.79.
D
Sell
2/23/2022Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 2/23/2022 due to a noticeable decline in the total return index and volatility index.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 2/23/2022 due to a noticeable decline in the total return index and volatility index.
D
Sell
11/23/2021Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 11/8/2021 due to a decline in the efficiency index, volatility index and valuation index. Net income declined 25.81% from -$22.94M to -$28.86M, and total capital declined 10.1% from $237.32M to $213.35M.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 11/8/2021 due to a decline in the efficiency index, volatility index and valuation index. Net income declined 25.81% from -$22.94M to -$28.86M, and total capital declined 10.1% from $237.32M to $213.35M.
D
Sell
3/16/2020Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 3/16/2020 due to an increase in the solvency index, efficiency index and growth index. Total capital increased 127.85% from $88.28M to $201.13M, the quick ratio increased from 7.02 to 15.25, and debt to equity declined from 0.01 to 0.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 3/16/2020 due to an increase in the solvency index, efficiency index and growth index. Total capital increased 127.85% from $88.28M to $201.13M, the quick ratio increased from 7.02 to 15.25, and debt to equity declined from 0.01 to 0.
D
Sell
3/11/2020Downgrade
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 3/11/2020 due to a decline in the volatility index.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to D- from D on 3/11/2020 due to a decline in the volatility index.
D
Sell
12/6/2019Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 12/6/2019 due to a noticeable increase in the total return index and volatility index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D from D- on 12/6/2019 due to a noticeable increase in the total return index and volatility index.
D
Sell
6/3/2019Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E on 6/3/2019 due to an increase in the volatility index, efficiency index and total return index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to D- from E on 6/3/2019 due to an increase in the volatility index, efficiency index and total return index.
E
Sell
3/4/2019Upgraded
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to E from E- on 3/4/2019 due to an increase in the total return index and valuation index.
Y-mAbs Therapeutics, Inc. (YMAB) was upgraded to E from E- on 3/4/2019 due to an increase in the total return index and valuation index.
E
Sell
12/17/2018None
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E- from U on 12/17/2018.
Y-mAbs Therapeutics, Inc. (YMAB) was downgraded to E- from U on 12/17/2018.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
